Less is More: The Art of Deprescribing in Geriatric Populations

November 18, 2026


File:VariousPills.jpgBy Maura Farinelli, Class of 2028

Peer Reviewed

“Houston, we have a problem.”1 America is aging, and it’s aging fast. Our population today is the oldest it has ever been, and the number of adults 65 and older is only slated to increase.2 Driven by the baby boomer generation, the US Census Bureau is projecting unprecedented growth of this age cohort in the next quarter century. By 2050, they predict adults 65 and over will comprise nearly a fourth of the entire US population, with an estimated 82 million individuals in this category.3

In contrast to our growing population of elders, the number of graduating medical students entering the field of Geriatrics is dwindling. According to the National Resident Matching Program data, less than half of available Geriatric Medicine fellowship positions have been filled in the last four years. The 2025 match marked a new low, with a fill rate of only 38.9%.4 Given that there are fewer than 7300 practicing geriatricians today, it is unlikely this number will grow to meet the 30,000 geriatricians the American Geriatric Society (AGS) predicts will be necessary by 2030.5 As such, it is imperative that all providers thoroughly familiarize themselves with the intricacies of geriatric medicine.

While there are many aspects to caring for older adults, one of the most nuanced is ensuring a proper pharmacological regimen. Astute medication management in geriatric populations is complex and does not always coincide with recommendations for the general adult population. Here is an introduction to best practices for approaching the pharmacologic needs of older patients–in particular, deprescribing as a clinical tool.

Due to the high degree of multimorbidity among older adults, rates of polypharmacy (the use of five or more medications simultaneously) are high within this population. With over 50% of elderly patients falling into this category, polypharmacy is often considered to be its own geriatric syndrome.6,7  It has been associated with increased hospitalizations, falls, adverse drug reactions, nonadherence, functional decline, cognitive impairment, and mortality.8,9,10 Moreover, polypharmacy remains the single greatest risk factor for the prescription of potentially inappropriate medications (PIMs).7

There have been initiatives to reduce polypharmacy in elderly patients using a systematic approach. The process has been termed deprescribing, and it involves methodically identifying and discontinuing medications that are potentially harmful, no longer confer benefit, or do not align with patient goals.7 Deprescribing is far from a one-way street, however. It requires a patient-centered approach and shared decision making for best outcomes.11 An overwhelming majority (88%) of patients are willing to discontinue medications when involved in conversations regarding their care.12

Deprescribing, when implemented thoughtfully, can lead to appreciable improvements in the outcomes of geriatric patients. Evidence from randomized controlled trials has demonstrated that targeted deprescribing interventions are effective in reducing polypharmacy and rates of PIM use in adults 65 and older.13 Within this age cohort, removal of medications has not been shown to increase hospitalizations, emergency department visits, or mortality, suggesting it is a safe practice.14 In fact, the implementation of targeted deprescribing interventions has been shown to reduce bad outcomes.15,16 Further benefits of such interventions include improved medication adherence and self-reported increases in overall health.17,18 Of note, deprescribing has shown similar patterns of benefit across multiple healthcare settings, including hospitals, post-acute care centers, and primary care centers.14,17

Several tools have been developed to assist in the process of deprescribing. The best known are the AGS Beers Criteria (developed in 1991), a list of drugs and drug classes the AGS considers to be potentially inappropriate for older adults.19 This resource serves as an excellent starting point for identifying possible medications to discontinue. That said, the patient’s clinical picture and care goals should ultimately be the deciding factor. The AGS Beers Criteria are not intended to absolutely contraindicate certain medications but rather to serve as a guide for best practice. Medication classes listed in the AGS Beers Criteria include anticholinergics, benzodiazepines, antipsychotics, antihistamines, and the hypnotic “Z-drugs” (eszopiclone, zaleplon, and zolpidem).19 Tools similar to the AGS Beers Criteria include the STOPP/START criteria and the Medications Associated with Geriatric Syndromes (MAGS) list, which also serve to identify PIMs in older adults.20,21

Despite the tools in place, there are several barriers to the effective implementation of deprescribing. At the patient level, fear of discontinuing a medication and poor health literacy can make removing agents difficult.22 It is important that providers take the time to educate their patients and engage them in shared decision-making. Prescribers face their own challenges with regard to deprescribing. The process often involves breaking away from disease-specific guidelines, which can be uncomfortable. However, older, frail adults are often excluded from the trials that inform these guidelines, which should embolden physicians to step outside the traditional clinical framework when it comes to these patients.7  These factors can be mitigated by the implementation of electronic health record flags, which have shown to increase rates of deprescribing in both hospitals and primary care centers.23,24

Deprescribing can feel daunting, especially for providers unfamiliar with the practice. Therefore, it is helpful to institute changes in a systematic manner. Not only does this make the process more manageable, it also maximizes the benefits and minimizes potential harm of drug discontinuation. One widely regarded protocol proposed by Scott and colleagues7  recommends the following five-step approach:

  1. Perform a full medication reconciliation. Determine all medications (including over-the-counter and supplements) the patient is taking and the indications for each. Gauge the patient’s perception toward each medication as well as adherence.
  2. Assess the patient’s overall risk of drug-induced harm. Consider drug factors such as the number of prescribed medications, use of high-risk drugs, and history of toxicity. Also consider patient factors such as age, comorbidities, and functional status.
  3. Determine which drugs should be discontinued. Use the Beers criteria to identify PIMs. Also look for drugs that have no valid indication, are part of a prescribing cascade (use of one drug to mitigate adverse effects of another drug), are ineffective, are not well-tolerated, or are indicated as primary prevention but are unlikely to confer benefit.
  4. Prioritize drugs to deprescribe. Target those with the greatest harm-to-benefit ratio, those that are easiest to discontinue (low likelihood of withdrawal or disease rebound), and those the patient is most willing to discontinue.
  5. Discontinue the drug and monitor the patient. Communicate clearly with the patient, caregivers, and other providers regarding the management plan. Remove one medication at a time to avoid misattributing harm or benefits of drug discontinuation. Monitor the patient for improvement, recurrence or progression of disease, or adverse withdrawal effects.

Deprescribing represents a paradigm shift that is common in Geriatrics and challenges physicians to look at the bigger picture. By recognizing polypharmacy as a modifiable risk factor and embracing deprescribing as a clinical skill, providers can meaningfully reduce harm and improve outcomes for older adults. Thus, the first lesson in our educational journey towards supporting an aging nation is quite simple: sometimes, less is more.

Maura Farinelli is a  Class of 2028 medical student at NYU Grossman School of Medicine

Peer Reviewed by Michael Tanner, MD Executive Editor, Clinical Correlations

Image Courtesy of Wikimedia Commons Creative Commons Attribution-Share Alike 3.0 Unported License

References

  1. Howard R, director. Apollo 13 [film]. Universal Pictures; 1995.
  2. Population Reference Bureau. Fact sheet: Aging in the United States. Population Reference Bureau; 2024. https://www.prb.org/resources/fact-sheet-aging-in-the-united-states/
  3. US Census Bureau. 2023 National Population Projections Tables: Main series [summary tables]. US Department of Commerce; 2023. https://www.census.gov/data/tables/2023/demo/popproj/2023-summary-tables.html
  4. National Resident Matching Program. Results and Data: Specialties Matching Service, 2025 Appointment Year [match data report]. 2025. https://www.nrmp.org/match-data/2025/02/results-and-data-specialties-matching-service-2025-appointment-year/
  5. American Geriatrics Society. Geriatrics for you. 2026. https://www.americangeriatrics.org/geriatrics-profession/why-geriatrics/geriatrics-for-you
  6. Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741. doi:10.1177/2042098620933741
  7. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med. 2015;175(5):827-834. doi:10.1001/jamainternmed.2015.0324
  8. Chang TI, Park H, Kim DW, et al. Polypharmacy, hospitalization, and mortality risk: A nationwide cohort study. Sci Rep. 2020;10(1):18964. doi:10.1038/s41598-020-75888-8
  9. Boateng I, Rodriguez Pascual C, Grassby P, Asghar Z, Ibrahim K. The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study. PLoS One. 2025;20(2):e0317907. doi:10.1371/journal.pone.0317907
  10. Hoel RW, Giddings Connolly RM, Takahashi PY. Polypharmacy management in older patients. Mayo Clin Proc. 2021;96(1):242-256. doi:10.1016/j.mayocp.2020.06.012
  11. Kim JL, Lewallen KM, Hollingsworth EK, Shah AS, Simmons SF, Vasilevskis EE. Patient reported barriers and enablers to deprescribing recommendations during a clinical trial (Shed-MEDS). 2023;63(3):523-533. doi:10.1093/geront/gnac100
  12. Chock YL, Wee YL, Gan SL, et al. How willing are patients or their caregivers to deprescribe: A systematic review and meta-analysis. J Gen Intern Med. 2021;36(12):3830-3840. doi:10.1007/s11606-021-06965-5
  13. Wang J, Shen JY, Conwell Y, et al. Implementation considerations of deprescribing interventions: A scoping review. J Intern Med. 2024;295(4):436-507. doi:10.1111/joim.13599
  14. Vasilevskis EE, Shah AS, Hollingsworth EK, et al. Deprescribing medications among older adults from end of hospitalization through postacute care: A Shed-MEDS randomized clinical trial. JAMA Intern Med. 2023;183(3):223-231. doi:10.1001/jamainternmed.2022.6545
  15. Carollo M, Crisafulli S, Vitturi G, et al. Clinical impact of medication review and deprescribing in older inpatients: A systematic review and meta-analysis. J Am Geriatr Soc. 2024;72(10):3219-3238. doi:10.1111/jgs.19035
  16. Kua CH, Yeo CYY, Tan PC, et al. Association of deprescribing with reduction in mortality and hospitalization: A pragmatic stepped-wedge cluster randomized controlled trial. J Am Med Dir Assoc. 2021;22(1):82-89.e3. doi:10.1016/j.jamda.2020.03.012
  17. Ulley J, Harrop D, Ali A, Alton S, Fowler Davis S. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: A systematic review. BMC Geriatr. 2019;19(1):15. doi:10.1186/s12877-019-1031-4
  18. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy. Arch Intern Med. 2010;170(18):1648-1654. doi:10.1001/archinternmed.2010.355
  19. American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372
  20. O’Mahony D, O’Sullivan D, Byrne S, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing. 2015;44(2):213-218. doi:10.1093/ageing/afu145
  21. Saraf AA, Petersen AW, Simmons SF, et al. Medications associated with geriatric syndromes and their prevalence in older hospitalized adults discharged to skilled nursing facilities. J Hosp Med. 2016;11(10):694-700. doi:10.1002/jhm.2614
  22. Ailabouni NJ, Weir KR, Reeve E, et al. Barriers and enablers of older adults initiating a deprescribing conversation. Patient Educ Couns. 2022;105(3):615-624. doi:10.1016/j.pec.2021.06.021
  23. McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study—Electronic decision support for deprescribing in hospitalized older adults: A cluster randomized clinical trial. JAMA Intern Med. 2022;182(3):265-273. doi:10.1001/jamainternmed.2021.7429
  24. Lauffenburger JC, Sung M, Glynn RJ, et al. Electronic health record intervention and deprescribing for older adults: A randomized clinical trial. 2026;335(12):1060-1069. doi:10.1001/jama.2025.26967

Leave a Reply

Your email address will not be published. Required fields are marked *